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Use of Sodium Bicarbonate in Cardiac Arrest: Current
Guidelines and Literature Review
Dimitrios Velissarisa, Vassilios Karamouzosa, Charalampos Pierrakosb, Ioanna Koniaric,
Christina Apostolopouloud, Menelaos Karanikolase, f

Abstract
The aim of the review was to summarize the literature over the last
25 years regarding bicarbonate administration in out-of-hospital cardiac arrest. A PubMed search was conducted using the terms “bicarbonates” and “cardiac arrest”, limited to human studies and reviews
published in English (or at least with a meaningful abstract in English) in the last 25 years. Clinical and experimental data raised questions regarding the safety and effectiveness of sodium bicarbonate
(SB) administration during cardiac arrest. Earlier advanced cardiac
life support (ACLS) guidelines recommended routine bicarbonate
administration as part of the ACLS algorithm, but recent guidelines
no longer recommend its use. The debate in the literature is ongoing,
but at the present time, SB administration is only recommended for
cardiac arrest related to hypokalemia or overdose of tricyclic antidepressants. Several studies challenge the assumption that bicarbonate
administration is beneficial for treatment of acidosis in cardiac arrest. At the present time, there is a trend against using bicarbonates in
cardiac arrest, and this trend is supported by guidelines published by
professional societies and organizations.
Keywords: Sodium bicarbonate; Cardiac arrest; Resuscitation; Metabolic acidosis

Introduction
Sodium bicarbonate (SB) administration has been considered
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an important part of treatment for severe metabolic acidosis in
cardiac arrest, because, based on pathophysiologic considerations, normalization of extracellular and intracellular pH was
considered a meaningful endpoint of resuscitation. Correction
of metabolic acidosis with SB was recommended by early advanced cardiac life support (ACLS) guidelines published in
1976 [1], and SB was the medication most frequently used during cardiac arrest until the mid-1980s [2]. However, because
of concerns regarding potential benefit vs. harm, SB use fell
progressively to almost no use by 1991, according to one study
from the UK [3]. At the present time, SB administration in cardiac arrest is controversial and matter of ongoing debate, and
frequency of use varies greatly between medical centers [4].
The 2010 ACLS guidelines for adults published by the American Heart Association (AHA) state that “Routine use of sodium
bicarbonate is not recommended for patients in cardiac arrest”
(class III recommendation, based on level of evidence (LOE)
B) [5], and these guidelines were not reviewed or revised in the
last update published in 2015 [6]. However, ACLS guidelines
recommend administration of SB 1 mL/kg boluses as needed
for hemodynamic stability (adequate mean arterial blood pressure) and QRS narrowing in cases of severe cardiotoxicity or
cardiac arrest from hyperkalemia or tricyclic antidepressant
overdose (class IIb recommendation, LOE C) [7], and this recommendation was not reviewed or revised in the last revision
of the ACLS guidelines published in 2015 [8]. The aim of this
review was to summarize the literature of the last 25 years regarding the potential benefit or harm of SB administration for
treatment of acidosis in patients with cardiac arrest.

Literature Search Methods
We conducted a PubMed database search using the terms “bicarbonate” and “cardiac arrest” in the “Title” field. The search
was conducted in March 2015, but was updated in November
2015, in order to include the latest update of the AHA guidelines for cardiopulmonary resuscitation. The search was limited to articles and reviews written in English, or articles written
in other languages but accompanied by a detailed meaningful
abstract in English, that were published in the last 25 years.
The bibliography from all extracted manuscripts was further
reviewed for identification of additional relevant references
which were included in this review.
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Literature Search Results
A retrospective study published by Roberts et al in 1990 attempted to identify predictors of mortality in patients resuscitated from cardiac arrest, and showed that survival was only
4.2% (10 of 238 patients) when SB was used vs. 27.8% (20
of 72 patients) when SB was not used, and this difference
was significant (P = 0.049). However, the authors pointed out
that poor survival in patients who received SB could reflect
more severe illness with presence of severe metabolic acidosis
among patients who required SB [9].
An observational cohort study published by Stiell et al in
1995 evaluated 529 patients who suffered cardiac arrest inside
or outside the hospital and received epinephrine according to
ACLS protocol guidelines. The study was conducted over a
2-year period and used univariate and multivariate logistic regression to assess the association between six ACLS drugs and
survival at 1 h and at hospital discharge. With the exception
of procainamide, all standard ACLS drugs, including SB, did
not have significant association with survival. However, the
authors noted that timing of drug administration could be an
important factor [10].
A prospective, randomized, double-blind trial published
by Dybvik et al in 1995 enrolled 502 adults who were resuscitated after out-of-hospital cardiac arrest due to asystole or ventricular fibrillation and failed the first defibrillation attempt.
The study compared outcomes in 245 patients who received
250 mL of SB-trometamol-phosphate mixture vs. 257 patients
who received 250 mL of 0.9% saline during resuscitation conducted in accordance with ACLS guidelines, and showed that,
although patients resuscitated after out-of-hospital cardiac arrest had metabolic acidosis, buffer therapy did not improve
outcome [11].
The benefit of medications recommended by ACLS support guidelines was questioned by a prospective cohort study
on 773 patients resuscitated after cardiac arrest published by
van Walraven et al in 1998. This study showed that only 269
of 773 patients survived the first hour. Multivariate logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) and showed significant association between unsuccessful resuscitation and use of epinephrine (OR:
0.08; 95% CI: 0.04 - 0.14), atropine (OR: 0.24; 95% CI: 0.17
- 0.35), bicarbonate (OR: 0.31; 95% CI: 0.21 - 0.44), calcium
(OR: 0.32; 95% CI: 0.18 - 0.55), and lidocaine (OR: 0.48; 95%
CI: 0.33 - 0.71). Despite the observed association between
bicarbonate use and unsuccessful outcome, the authors concluded that their study did not find association between ACLS
medications, including bicarbonate and successful resuscitation [12].
A review article published by Adgey and Johnston in 1999
assessed earlier publications and concluded that use of buffer
solutions should be limited to cardiac arrests where there is
documented severe acidosis, and should be given blindly only
after prolonged resuscitation, or in cardiac arrest associated
with hyperkalemia or tricyclic antidepressant overdose [13].
Similarly, a review published by Datta et al in 1999 assessed basic life support, advanced life support and post-resuscitation care, and concluded that routine use of bicarbonates
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was not recommended in cardiac arrest [14].
A large retrospective study published by Bar-Joseph et al
in 2002 based on the brain resuscitation clinical trial III, reviewed records from 2,915 patients and found a linear relationship between duration of ACLS and bicarbonate use. The brain
resuscitation clinical trial III was a multicenter randomized
trial comparing standard vs. high-dose epinephrine during cardiopulmonary resuscitation (CPR), while SB use was optional.
The authors concluded that, when bicarbonate was used, it was
probably used late, and suggested that, because of development of severe metabolic acidosis, bicarbonate administration
should start early [15]. However, these findings were contradicted by a second retrospective study published by Bar-Joseph
et al in 2005, which was also based on the brain resuscitation
clinical trial III database, except it only included patients with
out-of-hospital cardiac arrest where the time from collapse to
initiation of ACLS was shorter than 30 min, and included data
from 2,122 patients. The study groups included patients to
whom SB was administered in less than 50% of CPRs and first
epinephrine to spontaneous breathing time exceeded 10 min,
and groups where SB was administered in over 50% of CPRs
and first epinephrine to spontaneous breathing time was < 10
min. Multivariate regression analysis in this dataset showed
that earlier and more frequent use of SB was related to improved chance of return of spontaneous circulation (ROSC)
and better long-term outcome [4].
Vukmir and Katz published in 2006 the results of a prospective randomized, double-blinded pre-hospital clinical trial
that was conducted in Pennsylvania between 1994 and 1998,
before early defibrillation by first responders was introduced
to clinical practice. Of 874 registered potentially eligible patients with pre-hospital cardiopulmonary arrest, 792 patients
were enrolled in the study. The primary outcome was ROSC
or arrival to the emergency department with a pulse. The experimental group (420 patients) received 1 mEq/kg of SB after standard ACLS interventions, whereas the control group
(372 patients) received equal volume of normal saline. Overall, there was no difference in survival, as 58 of 420 patients
(13.9%) survived in the bicarbonate group, compared to 52 of
320 (13.8%) in the control group. However, in the subgroup
of patients with prolonged (longer than 15 min) pre-hospital
cardiac arrest, survival was 32.8% in the bicarbonate group
vs. 15.4% in the control group, and the difference was highly
significant (P = 0.007) [16].
A review article published by Spohr et al in 2008 concluded that only a few drugs conferred a proven benefit for
short-term survival after cardiac arrest, and suggested that bicarbonates should only be administered during CPR if indicated based on arterial blood gas analysis or in cases of prolonged
unsuccessful resuscitation [17].
A retrospective study published by Geraci et al in 2009
reviewed medical records of 88 patients who received SB during cardiac arrest and showed that 27 of 88 patients (31%) received SB without arterial blood gas (ABG) data. In patients
where ABG data were available, bicarbonate administration
was linked to alkalemia in 16% (10 of 61) of patients. The
authors suggested that early ABG analysis in cardiac arrest
may help optimize pH and reduce the frequency of empiric,
not warranted, bicarbonate use [18].
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Table 1. Clinical Studies Evaluating the Effect of Sodium Bicarbonate in Cardiac Arrest
Author

Origin, year

Study design

Findings

Aufderheide et al [24]

Wisconsin, USA, 1992

Retrospective chart review, 619 arrest pts, No association between SB and survival
273 had ROSC

Bar-Joseph et al [15]

Pittsburgh, PA, USA, 2002

Retrospective study, 2,915 pts from brain
resuscitation clinical trial III dataset

SB given in 54% of cases, use
increased with ACLS duration. SB
should probably be given earlier.

Bar-Joseph et al [4]

Pittsburgh, PA, USA, 2005

Retrospective study, 2,122 pts from brain
resuscitation clinical trial III dataset with
ACLS lasting < 30 min

Earlier and more frequent use of SB
associated with higher resuscitation
rates and better long-term outcome

Bishop and
Weisfeldt [25]

Baltimore, MD, 1976

Experimental data from seven dogs,
clinical data from six cardiac arrest pts

SB increases PCO2, accentuates
intracellular acidosis in poorly
ventilated pts, may be useful
in well-ventilated pts

Delooz and Lewi [25]

Leuven, Belgium, 1989

Retrospective data analysis

SB > 1 mEq/kg associated with poor
outcome

Dybvik et al [11]

Oslo, Norway, 1995

RCT, SB (245 pts) vs. 0.9% NS (257 pts)

SB therapy had no effect on outcome

Geraci et al [18]

Jacksonville, FL, USA, 2009

Retrospective chart review, all CPR cases
in 2005 - 2006, 88 pts received SB

SB linked with alkalemia in 16% of pts,
recommendation for early collection of
ABG sample

Mattar et al [22]

Los Angeles, CA, USA, 1974

Case series, 12 pts, SB in cardiac arrest

Plasma osmolality > 400 mOsm/kg,
serum Na concentrations > 200 mEq/L

Roberts et al [9]

Winnipeg, Manitoba,
Canada, 1990

Retrospective study, 326 pts

Survival 4.2% (10/238) when SB given
vs. 27.8% (20/72) when SB not given
(P = 0.049) but SB use may reflect
presence of severe acidosis

Stiell et al [10]

Ottawa, ON, Canada, 1995

Observational cohort study, 529 pts in 2
years received epi per ACLS guidelines

Logistic regression did not show
association between SB and survival

Suljaga-Pechtel
et al [27]

New York, NY, USA, 1984

Prospective observational study, 277
arrests in 226 pts

Survival lower in pts who needed SB,
likely due to illness severity

van Walraven [12]

Ottawa, ON, Canada, 1998

Prospective cohort study, 773 pts with
cardiac arrest, logistic regression for OR
and 95% CI

269 of 773 pts survived the first hour.
SB use significantly associated with
unsuccessful resuscitation

Vukmir and Katz [16]

Pittsburgh, USA, 2006

RCT, 792 patients, SB (420 pts) vs.
placebo (372 pts)

Overall survival 13.9% (110/792),
no difference between groups.
Trend for improved survival with
SB in prolonged (> 15 min) arrest

Weaver et al [28]

Seattle, WA, USA, 1990

RCT, lidocaine (n = 106) vs. epi (n =
93); historical controls (n = 132) for SB

Higher survival with SB infusion,
which was done before the study started

Weil et al [23]

Chicago, IL, USA, 1985

Cohort study, 105 cardiac arrest pts, all
received SB

Survival lower if pH > 7.55 within 10
min of CPR

Weng et al [21]

Taiwan, 2013

Retrospective cohort, 92 pts (30 with vs.
62 without SB)

SB did not improve rate of ROSC in
prolonged (> 15 min) cardiac arrest

ABG: arterial blood gas; ACLS: advanced cardiac life support; CI: confidence interval; CPR: cardiopulmonary resuscitation; min: minutes; epi: epinephrine; pts: patients; OR: odds ratio; RCT: randomized controlled trial; ROSC: return of spontaneous circulation; SB: sodium bicarbonate.

A review from Lee in 2011 mentioned the role of drugs
administration after effective CPR and defibrillation in the cardiac arrest, but based on randomized trials, no drugs or combination of them have shown benefit on long-term survival [19].
A review by Williamson et al in 2012 reported that although short-term outcomes after CPR have improved as result
of the administration of code drugs, in most cases there was no

significant benefit with regard to the final outcome [20].
A retrospective cohort study published by Weng et al in
2013 included data from 92 patients who presented to the
emergency department with cardiac arrest. The authors compared 30 patients who received vs. 62 patients who did not
receive SB, in an attempt to assess the effect of bicarbonate
administration after prolonged (> 15 min) CPR. Although
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patients who received bicarbonate had higher percentage of
ROSC, regression analysis showed that bicarbonate administration did not significantly improve the rate of ROSC in outof-hospital cardiac arrest [21]. The findings of all the above
clinical studies are summarized in Table 1 [4, 9-12, 15, 16,
18, 21-28]. Studies in the table are listed in alphabetical order
based on the first author’s last name.

Discussion
Debate regarding the potential benefit vs. harm from administration of SB in CPR has been ongoing for decades. Bicarbonate administration was recommended by early ACLS
guidelines published in 1976 [1], and this recommendation
continued when these guidelines were updated in 1980 [29],
but concern about potential harm made bicarbonate use in cardiac arrest increasingly controversial in recent years. As significant acidosis is related to serious adverse systemic effects,
bicarbonate administration seems a reasonable intervention to
counteract the severe metabolic acidosis caused by hypoxia,
poor perfusion and increased lactate production in cardiac arrest, in an attempt to mitigate the adverse effects of acidosis,
improve response to exogenously administered catecholamines and increase venous return, thereby improving coronary
perfusion pressure [30].
Failure of ventilation and perfusion in cardiac arrest causes severe disruption of homeostasis. Tissue hypoxia from hypoventilation or poor perfusion leads to anaerobic metabolism
with reduced adenosine triphosphate (ATP) generation and
increased lactic acid accumulation, thereby resulting in metabolic acidosis with plasma pH < 7.20 and increased lactate
levels [31, 32]. In addition, respiratory failure with compromised ventilation reduces CO2 elimination, resulting in CO2
accumulation and respiratory acidosis. Severe combined metabolic and respiratory acidosis and impaired oxygen tissue delivery result in cell damage, as evidenced by cardiac dysfunction from decreased myocardial contractility, hypotension, and
renal, hepatic and central nervous system injury that can progress to multi-organ failure. Because of concerns regarding the
deleterious effects of acidosis, clinicians have used bicarbonates as buffer to offset the high acid production, in an attempt
to help the body restore normal homeostasis in cardiac arrest.
Data published in the 1970s raised concerns that SB administration during cardiac arrest can worsen the outcome after cardiac arrest and emphasized the adverse effects of bicarbonates, including increased osmolality [22]. These concerns
were supported by experimental animal studies showing that
administration of SB can have adverse effects in dogs with hypoxic lactic acidosis [33], and by clinical data showing that
patients with cardiac arrest who received SB in accordance
with then current ACLS guidelines had sharply lower survival
if pH > 7.55 in the first 10 min after resuscitation started [23].
These arguments were rebutted in a review published in 1987
by Narins and Cohen entitled “Bicarbonate therapy for organic
acidosis: the case for its continued use” [34]. However, newer
data from experiments in pigs showed that hypertonic buffer
solutions in the absence of vasopressors can reduce coronary
perfusion pressure below critical thresholds during cardiac
280
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arrest and CPR, and may adversely affect outcome [35]. In
contrast, an experimental study published by Liu et al in 2002
showed that administration of bicarbonate buffer solution
promoted cerebral reperfusion and mitigated cerebral acidosis after restoration of spontaneous circulation in piglets [36].
Similarly, data from experiments with CPR in rats suggested
that administration of SB or other buffer solutions can improve
survival by ameliorating post-arrest myocardial dysfunction
[37]. However, despite encouraging experimental data, concerns about possible detrimental effects of SB administration
in cardiac arrest remain.
Few human studies have examined the benefits of bicarbonate administration in cardiac arrest, and most of them are
dated before 1990, at a time when SB administration was routine during CPR, even though the acid-base status of patients
was not known in the majority of cases. However, that practice
has changed over the years due to concerns about adverse effects of bicarbonate administration and the fact that published
clinical studies failed to show specific benefits from their use
[11, 24, 25, 38].
Published data in recent years suggest that SB administration can have deleterious effects during cardiac arrest, including increased intracellular acidosis, reduced cardiac output,
shift of the oxygen dissociation curve to the left, with increased
affinity of hemoglobin for oxygen resulting in reduced oxygen
tissue release, hypernatremia and hyperosmolarity [39]. As increased blood and tissue CO2 concentration leads to worsening
of tissue acidosis in major organs, including the heart, possibly
contributing to cardiac dysfunction, it may be detrimental to
cardiac resuscitation [26, 40-43].
In response to concerns raised by these studies, routine use
of SB in cardiac arrest has been discouraged, and the AHA has
deemphasized its use in the ACLS algorithms [5]. The main
goal in cardiac arrest treatment is to intervene as early as possible, with emphasis on early activation of the emergency response system, early initiation of CPR and early defibrillation,
in an attempt to improve outcome. Drug administration still
has a role in attempts to improve organ perfusion during CPR,
facilitate electrical defibrillation, reduce myocardial irritability, terminate malignant ventricular arrhythmias, minimize
metabolic derangements and protect the brain from the effects
of ischemia [44].
Buffering solutions other than SB have also been used to
correct the metabolic acidosis during cardiac arrest. A review
published in 1998 by Bjerneroth reported that different alkaline buffers have been used, but have not shown any benefit
because of numerous deleterious effects [45]. Tribonat, a mixture of THAM, acetate, SB and phosphate, has been proposed
as suitable alternative to conventional buffer solutions. A review published by Bjerneroth in 1999 assessed 76 publications
and, although it did not find improvement in overall survival,
it suggested that Tribonat may be superior compared to previously used buffer solutions in cases where administration of an
alkalinizing agent is indicated [46].
Some studies have suggested a beneficial role for bicarbonate in the treatment of metabolic acidosis associated with cardiac arrest of prolonged duration, while other studies showed
that bicarbonate administration may be counter-productive
because it increases tissue and central venous blood carbon di-
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oxide tension. Decisions regarding bicarbonate administration
should therefore be based on central venous blood gas analysis
[47]. Historically, a report by Stewart in 1964 described 12
cases of cardiac arrest and, although it showed that correction
of metabolic acidosis increased the chances of successful treatment, it also suggested that bicarbonate administration is not
warranted in all cardiac arrest cases [48]. A retrospective study
published by Aufderheide et al in 1992 reviewed data from
3 years of clinical experience with use of SB in 273 patients
successfully resuscitated from cardiac arrest, and assessed the
potential harms from bicarbonate use. The Aufderheide study
showed that 2% (four of 215) of patients who received SB had
hypernatremia, but there was no difference with regard to alkalosis, and because of study design limitations, the authors
could not determine the influence of bicarbonate use on survival [24]. Also a review by Vukmir et al published in 1996
analyzed all studies before that time showing that six of nine
studies reported some prolongation of survival time after cardiac arrest, with one study reporting worse outcome and two
studies showing no effect of bicarbonate on survival, but most
of these studies were uncontrolled [30]. A brief review published by Professor Adgey in “Heart” in 1998 suggested that,
based on available evidence, the mainstay for maintenance of
acid-base balance in cardiac arrest is adequate alveolar ventilation. The review recommended that treatment with SB should
be reserved for cardiac arrest patients in one of the following
four groups: 1) severe acidosis with arterial pH < 7.1 and base
excess < 10), 2) patients with prolonged (> 10 - 20 min) cardiac arrest, 3) cardiac arrest related to hyperkalemia, or 4) cardiac arrest related to overdose of tricyclic antidepressants [39].
Although SB use has been part of standard therapy for
treatment of acidosis in cardiac arrest, data published over the
last 25 years do not support its use. The AHA revised the ACLS
guidelines since the 2000 edition of standards and guidelines
for CPR and emergency cardiac care (ECC), so that SB administration is only advised at the discretion of the physician
directing the resuscitation. In cases where clinicians choose
to administer bicarbonates, SB should be given as IV bolus
or by IV infusion, with standard dose being 1 mg/kg of body
weight as initial dose, followed by 0.5 mg/kg every 10 min
for the duration of the arrest. A 50-mL bolus of SB will raise
serum pH approximately 0.1 of a pH unit [7]. The 2010 revised
AHA guidelines for CPR and ECC emphasize that acidosis and
acidemia are dynamic processes resulting from the absence of
blood flow in cardiac arrest [5], therefore high quality CPR and
early defibrillation in attempt to restore spontaneous circulation are the best methods to restore acid-base balance, with additional benefit gained by ventilation. The majority of studies
cited in these guidelines showed poor outcomes and no benefit
from bicarbonate administration, while only two studies demonstrated increased ROSC and survival to hospital discharge.
In addition, the AHA 2010 ACLS guidelines mentioned significant potential adverse effects related to bicarbonate administration during cardiac arrest, including inactivation of simultaneously administered catecholamines, reduction of systemic
vascular resistance, hypernatremia, hyperosmolality and extracellular alkalosis despite intracellular PCO2 excess [7].
Because of the above reservations, current ACLS guidelines recommend bicarbonate administration only in cases of

cardiac arrest related to hyperkalemia or tricyclic antidepressant overdose [7]. Clinicians can repeat the bicarbonate dose
according to patients’ clinical status or based on results of
blood gas analysis. Alternative, non-CO2 generating buffers,
such as THAM and Tribonate, have potential for minimizing
the adverse effects of SB, but clinical experience and outcome
data are very limited.
Last, according to the ACLS guidelines published by the
AHA, routine SB administration is not recommended in the
ACLS protocol for pulseless electrical activity, and this is a
class III recommendation, based on LOE B (limited populations evaluated, data derived from a single randomized trial or
non-randomized studies) [5].

Conclusion
Although many studies have shown little/no benefit and perhaps harm from administration of SB for rapid correction of
acidemia accompanying cardiac arrest, and the latest ACLS
guidelines published by the AHA do not recommend routine
administration, SB is still used as part of resuscitation in cardiac arrest. Additional research is needed to elucidate further
the effects of SB on organ function, on the likelihood of ROSC
and on survival in patients resuscitated from cardiac arrest. An
objective reappraisal of the use of SB or other buffer agents
and perhaps on an appropriate “therapeutic window” for use of
SB in cardiac arrest patients is warranted.

Conflicts of Interest
This work was supported solely by department funds. All authors state that they do not have any conflicts of interest to
report.

Author Contributions
DV did literature search and wrote the manuscript; VK assisted
with literature search and edited manuscript; CP collected data
and edited manuscript; IK reviewed the literature and edited
manuscript; CA did literature search and edited manuscript;
MK reviewed the literature, edited and finalized the manuscript.

References
1.
2.

3.

Standards for cardiopulmonary resuscitation (CPR) and
emergency cardiac care (ECC). 3. Advanced life support.
JAMA. 1974;227(7 Suppl):852-860.
Batenhorst RL, Clifton GD, Booth DC, Hendrickson NM,
Ryberg ML. Evaluation of 516 cardiopulmonary resuscitation attempts. Am J Hosp Pharm. 1985;42(11):24782483.
Levy RD, Rhoden WE, Shearer K, Varley E, Brooks NH.
An audit of drug usage for in-hospital cardiopulmonary

Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press Inc™ | www.jocmr.org

281

Sodium Bicarbonate in Cardiac Arrest

4.

5.

6.

7.

8.

9.
10.

11.
12.

13.
14.
15.

16.
17.
282

resuscitation. Eur Heart J. 1992;13(12):1665-1668.
Bar-Joseph G, Abramson NS, Kelsey SF, Mashiach T,
Craig MT, Safar P. Improved resuscitation outcome in
emergency medical systems with increased usage of sodium bicarbonate during cardiopulmonary resuscitation.
Acta Anaesthesiol Scand. 2005;49(1):6-15.
Neumar RW, Otto CW, Link MS, Kronick SL, Shuster
M, Callaway CW, Kudenchuk PJ, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart
Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation.
2010;122(18 Suppl 3):S729-767.
Link MS, Berkow LC, Kudenchuk PJ, Halperin HR,
Hess EP, Moitra VK, Neumar RW, et al. Part 7: Adult
Advanced Cardiovascular Life Support: 2015 American
Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
Circulation. 2015;132(18 Suppl 2):S444-464.
Vanden Hoek TL, Morrison LJ, Shuster M, Donnino M,
Sinz E, Lavonas EJ, Jeejeebhoy FM, et al. Part 12: cardiac arrest in special situations: 2010 American Heart
Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation.
2010;122(18 Suppl 3):S829-861.
Lavonas EJ, Drennan IR, Gabrielli A, Heffner AC, Hoyte
CO, Orkin AM, Sawyer KN, et al. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation.
2015;132(18 Suppl 2):S501-518.
Roberts D, Landolfo K, Light RB, Dobson K. Early predictors of mortality for hospitalized patients suffering
cardiopulmonary arrest. Chest. 1990;97(2):413-419.
Stiell IG, Wells GA, Hebert PC, Laupacis A, Weitzman
BN. Association of drug therapy with survival in cardiac
arrest: limited role of advanced cardiac life support drugs.
Acad Emerg Med. 1995;2(4):264-273.
Dybvik T, Strand T, Steen PA. Buffer therapy during outof-hospital cardiopulmonary resuscitation. Resuscitation.
1995;29(2):89-95.
van Walraven C, Stiell IG, Wells GA, Hebert PC, Vandemheen K. Do advanced cardiac life support drugs increase
resuscitation rates from in-hospital cardiac arrest? The
OTAC Study Group. Ann Emerg Med. 1998;32(5):544553.
Adgey AA, Johnston PW. Approaches to modern management of cardiac arrest. Heart. 1998;80(4):397-401.
Datta S, Nasr NF, Khorasani A, Datta R. Current concepts
in cardiopulmonary resuscitation in adults. J Indian Med
Assoc. 1999;97(7):259-264, 270.
Bar-Joseph G, Abramson NS, Jansen-McWilliams L,
Kelsey SF, Mashiach T, Craig MT, Safar P. Clinical use
of sodium bicarbonate during cardiopulmonary resuscitation - is it used sensibly? Resuscitation. 2002;54(1):4755.
Vukmir RB, Katz L. Sodium bicarbonate improves outcome in prolonged prehospital cardiac arrest. Am J Emerg
Med. 2006;24(2):156-161.
Spohr F, Wenzel V, Bottiger BW. Thrombolysis and other

J Clin Med Res. 2016;8(4):277-283

18.

19.
20.

21.

22.
23.
24.

25.

26.
27.

28.

29.
30.
31.
32.
33.
34.

drugs during cardiopulmonary resuscitation. Curr Opin
Crit Care. 2008;14(3):292-298.
Geraci MJ, Klipa D, Heckman MG, Persoff J. Prevalence
of sodium bicarbonate-induced alkalemia in cardiopulmonary arrest patients. Ann Pharmacother. 2009;43(7):12451250.
Lee SW. Drugs in resuscitation: an update. Singapore
Med J. 2011;52(8):596-602.
Williamson K, Breed M, Alibertis K, Brady WJ. The
impact of the code drugs: cardioactive medications in
cardiac arrest resuscitation. Emerg Med Clin North Am.
2012;30(1):65-75.
Weng YM, Wu SH, Li WC, Kuo CW, Chen SY, Chen
JC. The effects of sodium bicarbonate during prolonged
cardiopulmonary resuscitation. Am J Emerg Med.
2013;31(3):562-565.
Mattar JA, Weil MH, Shubin H, Stein L. Cardiac arrest in
the critically ill. II. Hyperosmolal states following cardiac
arrest. Am J Med. 1974;56(2):162-168.
Weil MH, Ruiz CE, Michaels S, Rackow EC. Acid-base
determinants of survival after cardiopulmonary resuscitation. Crit Care Med. 1985;13(11):888-892.
Aufderheide TP, Martin DR, Olson DW, Aprahamian C,
Woo JW, Hendley GE, Hargarten KM, et al. Prehospital
bicarbonate use in cardiac arrest: a 3-year experience. Am
J Emerg Med. 1992;10(1):4-7.
Delooz HH, Lewi PJ. Are inter-center differences
in EMS-management and sodium-bicarbonate administration important for the outcome of CPR? The
Cerebral Resuscitation Study Group. Resuscitation.
1989;17(Suppl):S161-172; discussion S199-206.
Bishop RL, Weisfeldt ML. Sodium bicarbonate administration during cardiac arrest. Effect on arterial pH PCO2,
and osmolality. JAMA. 1976;235(5):506-509.
Suljaga-Pechtel K, Goldberg E, Strickon P, Berger M,
Skovron ML. Cardiopulmonary resuscitation in a hospitalized population: prospective study of factors associated
with outcome. Resuscitation. 1984;12(2):77-95.
Weaver WD, Fahrenbruch CE, Johnson DD, Hallstrom
AP, Cobb LA, Copass MK. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to
ventricular fibrillation. Circulation. 1990;82(6):20272034.
Standards and guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiac care (ECC). JAMA.
1980;244(5):453-509.
Vukmir RB, Bircher N, Safar P. Sodium bicarbonate in cardiac arrest: a reappraisal. Am J Emerg Med.
1996;14(2):192-206.
Mizock BA, Falk JL. Lactic acidosis in critical illness.
Crit Care Med. 1992;20(1):80-93.
Stacpoole PW. Lactic acidosis. Endocrinol Metab Clin
North Am. 1993;22(2):221-245.
Graf H, Leach W, Arieff AI. Metabolic effects of sodium bicarbonate in hypoxic lactic acidosis in dogs. Am J
Physiol. 1985;249(5 Pt 2):F630-635.
Narins RG, Cohen JJ. Bicarbonate therapy for organic
acidosis: the case for its continued use. Ann Intern Med.
1987;106(4):615-618.

Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press Inc™ | www.jocmr.org

Velissaris et al

J Clin Med Res. 2016;8(4):277-283

35. Kette F, Weil MH, Gazmuri RJ. Buffer solutions may
compromise cardiac resuscitation by reducing coronary
perfusion presssure. JAMA. 1991;266(15):2121-2126.
36. Liu X, Nozari A, Rubertsson S, Wiklund L. Buffer administration during CPR promotes cerebral reperfusion after return of spontaneous circulation and mitigates post-resuscitation cerebral acidosis. Resuscitation.
2002;55(1):45-55.
37. Sun S, Weil MH, Tang W, Fukui M. Effects of buffer
agents on postresuscitation myocardial dysfunction. Crit
Care Med. 1996;24(12):2035-2041.
38. Papastylianou A, Mentzelopoulos S. Current pharmacological advances in the treatment of cardiac arrest. Emerg
Med Int. 2012;2012:815857.
39. Adgey AA. Adrenaline dosage and buffers in cardiac arrest. Heart. 1998;80(4):412-414.
40. Adrogue HJ, Rashad MN, Gorin AB, Yacoub J, Madias
NE. Assessing acid-base status in circulatory failure. Differences between arterial and central venous blood. N
Engl J Med. 1989;320(20):1312-1316.
41. Arieff AI, Leach W, Park R, Lazarowitz VC. Systemic ef-

42.
43.
44.
45.

46.
47.
48.

fects of NaHCO3 in experimental lactic acidosis in dogs.
Am J Physiol. 1982;242(6):F586-591.
Arieff AI. Indications for use of bicarbonate in patients
with metabolic acidosis. Br J Anaesth. 1991;67(2):165177.
Kraut JA, Kurtz I. Use of base in the treatment of severe
acidemic states. Am J Kidney Dis. 2001;38(4):703-727.
Vincent R. Drugs in modern resuscitation. Br J Anaesth.
1997;79(2):188-197.
Bjerneroth G. Alkaline buffers for correction of metabolic
acidosis during cardiopulmonary resuscitation with focus
on Tribonat - a review. Resuscitation. 1998;37(3):161171.
Bjerneroth G. Tribonat - a comprehensive summary of its
properties. Crit Care Med. 1999;27(5):1009-1013.
Steedman DJ, Robertson CE. Acid base changes in arterial and central venous blood during cardiopulmonary
resuscitation. Arch Emerg Med. 1992;9(2):169-176.
Stewart JS. Management of Cardiac Arrest, with Special Reference to Metabolic Acidosis. Br Med J.
1964;1(5381):476-479.

Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press Inc™ | www.jocmr.org

283

